The effect of enoxaparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention patients

Abstract

Aim:The aim of the present study was to investigate the effects of enoxaparin on in vitro stimulated platelet aggregation by elective percutaneous coronary intervention patients. Method:Twenty-two patients that scheduled for elective percutaneous coronary angioplasty (PTCA) were enrolled in the present study. The patients who had not been taking any antiaggregant agent other than aspirin and normal platelet account received enoxaparin (1mg/kg IV bolus) as anticoagulant agent during PTCA. Two blood samples were obtained for every patient via femoral arterial sheath during the intervention before and 10 minutes after enoxaparin administration and stimulated platelet aggregation responses are investigated. Results:The decrease in platelet aggregation responses to adenosine diphosphate (ADP), collagen and epinephrine before and after enoxaparin administration were statistically significant (p<0.05). The decrease in platelet aggregation response to ristocetin before and after enoxaparin was not statistically significant (p>0.05). Conclusion:Enoxaparin may reduce platelet aggregation in elective PTCA patients pretreated with aspirin only.With the knowledge of the importance of the platelet inhibition, choice of the anticoagulant agent during PTCA may be beneficial.Keywords: Enoxaparin, stimulated platelet aggregation, elective PTCA Abstract EJCM 2017; 05 (2):